First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00455936 |
Recruitment Status
:
Completed
First Posted
: April 4, 2007
Last Update Posted
: October 25, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The investigators will conduct the randomized trial to determine the role of Gefitinib monotherapy as first-line setting in adenocarcinoma patients with no history of smoking, as compared with the standard combination chemotherapy.
This is a randomized, open label, parallel group, phase III study in never-smokers with advanced or metastatic adenocarcinoma of lung.
After stratification by gender, performance status, and disease stage, patients will be randomized to one of the two treatment arms to receive either gefitinib or standard chemotherapy until clinical or objective disease progression, unacceptable toxicity or patient's refusal, whichever is sooner. The chemotherapy will be administered for no more than nine cycles.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Cancer | Drug: Gefitinib Procedure: chemotherapy | Phase 3 |
Gefitinib (Iressa TM) Arm - Gefitinib administration 250mg tablet once daily every 3 weeks
standard chemotherapy arm - gemcitabine (1,250mg/m2 for 30 minutes on day 1 and 8 of a 3 week cycle) plus cisplatin (80mg/m2 on day 1 of a 3 week cycle)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 315 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung |
Study Start Date : | October 2005 |
Actual Primary Completion Date : | November 2009 |
Actual Study Completion Date : | March 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: study arm
Gefitinib 250mg table/QD, daily every 3 weeks
|
Drug: Gefitinib
gefitinib 250mg tablet/ QD daily until Progression
Other Name: Treamtment Arm
|
Active Comparator: control arm
gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
|
Procedure: chemotherapy
gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
Other Name: standard chemotherapy arm
|
- overall survival [ Time Frame: every 12 weeks ]
- To compare Progression-Free survival [ Time Frame: every 9 weeks ]
- To compare the quality of life [ Time Frame: every 3 weeks ]
- To compare safety profile [ Time Frame: every 9 weeks ]
- To collect the tissue samples for the study of predictors of gefitinib (optional) [ Time Frame: screening period ]
- To compare the objective response rate (CR+PR) [ Time Frame: from the date of randomization to the date of death from any cause the result of each should be recorded separately ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of adenocarcinoma of lung with or without BAC features; however, adenocarcinoma combined with other histology, such as small cell carcinoma or squamous carcinoma, is not allowed.
- Stage IIIB with malignant pleural effusion/pleural seeding or stage IV patients
- Age 18-75
- Never-smoking defined as not more than 100 cigarettes during the lifetime
- ECOG performance status of 0-2
- No prior invasive malignancies 5 years prior to study entry except adequately treated cutaneous basal cell carcinoma or uterine cervix in situ cancer
- Serum creatinine ≤ 1.5 mg/dL, serum bilirubin ≤ 1.2 mg/dL (1 x UNL) and SGOT/SGPT ≤ 100 IU/L (2.5 x UNL)
- Serum Hgb ≥ 10 gm/dl, platelet count ≥ 100,000/ul, total WBC count >= 4,000/uL, absolute neutrophil count ≥ 1,500/ul
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital. The only approved consent form is attached to this protocol
- The presence of CNS metastases is not considered as an exclusion criterion, provided that there is good control of the symptoms with corticosteroids
Exclusion Criteria:
- Pregnancy or breast-feeding (women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.
- Major surgery other than biopsy within the past two week.
- Known severe hypersensitivity to Gefitinib or any of the excipients of this product
- Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)
- As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
- Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort
- Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455936
Korea, Republic of | |
National Cancer Center, Korea | |
Goyang-si, Gyenggi-do, Korea, Republic of, 411-769 | |
Samsung Medical Center | |
Seoul, Korea, Republic of, 135-710 | |
Asan Medical Center | |
Seoul, Korea, Republic of, 138-736 |
Study Chair: | Jin Soo Lee, M.D. | National Cancer Center, Korea |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Jin Soo Lee, National Cancer Center, Korea |
ClinicalTrials.gov Identifier: | NCT00455936 History of Changes |
Other Study ID Numbers: |
NCCCTS-05-126 D7913L00054 ( Other Grant/Funding Number: AstraZeneca ) |
First Posted: | April 4, 2007 Key Record Dates |
Last Update Posted: | October 25, 2010 |
Last Verified: | March 2010 |
Keywords provided by National Cancer Center, Korea:
Adenocarcinoma NSCLC gemcitabine |
Cisplatin Gefitinib Never smoker |
Additional relevant MeSH terms:
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gemcitabine Gefitinib Cisplatin Antineoplastic Agents Antimetabolites, Antineoplastic |
Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Protein Kinase Inhibitors |